Tobacco quitline use: enhancing benefit and increasing abstinence
- PMID: 18675528
- DOI: 10.1016/j.amepre.2008.06.032
Tobacco quitline use: enhancing benefit and increasing abstinence
Abstract
Objective: This study sought to evaluate the impact on the quitline utilization and abstinence rates of increasing a free nicotine-replacement therapy (NRT) benefit from 4 weeks to 6 weeks.
Methods: Intake data were utilized to assess the number of callers to the quitline during the time period in which 4 weeks of free NRT was provided (January-November 2006) and the time period of the enhanced NRT benefit (December 2006-June 2007). Abstinence rates at 3 and 6 months were calculated for people utilizing the quitline program during both time periods.
Results: The mean number of intake calls to the quitline increased from 397 (range 326-509) prior to the enhanced NRT benefit to 712 (range 592-1227) during the 6-week NRT benefit period. The 6-month tobacco abstinence rates were significantly higher among people receiving the 6-week NRT benefit compared to those receiving the 4-week benefit (OR=1.51; 95% CI=1.07, 1.66).
Conclusions: The findings suggest that the promotion of an expanded NRT benefit can increase quitline utilization and abstinence rates.
Similar articles
-
Nicotine patches and uninsured quitline callers. A randomized trial of two versus eight weeks.Am J Prev Med. 2008 Aug;35(2):103-10. doi: 10.1016/j.amepre.2008.04.017. Am J Prev Med. 2008. PMID: 18617079 Clinical Trial.
-
Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.Nicotine Tob Res. 2010 Jun;12(6):567-73. doi: 10.1093/ntr/ntq045. Epub 2010 Apr 8. Nicotine Tob Res. 2010. PMID: 20378640
-
Use and effectiveness of tobacco telephone counseling and nicotine therapy in Maine.Am J Prev Med. 2005 Nov;29(4):288-94. doi: 10.1016/j.amepre.2005.06.015. Am J Prev Med. 2005. PMID: 16242591
-
Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?Health Policy. 2008 Apr;86(1):17-26. doi: 10.1016/j.healthpol.2007.08.006. Epub 2007 Nov 1. Health Policy. 2008. PMID: 17935827 Review.
-
Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases.Mutat Res. 2009 Jul 10;667(1-2):44-57. doi: 10.1016/j.mrfmmm.2008.10.015. Epub 2008 Nov 5. Mutat Res. 2009. PMID: 19028511 Review.
Cited by
-
Telephone counselling for smoking cessation.Cochrane Database Syst Rev. 2019 May 2;5(5):CD002850. doi: 10.1002/14651858.CD002850.pub4. Cochrane Database Syst Rev. 2019. PMID: 31045250 Free PMC article.
-
Examining the significance of urban-rural context in tobacco quitline use: does rurality matter?Int J Public Health. 2015 Mar;60(3):327-33. doi: 10.1007/s00038-014-0634-y. Epub 2014 Dec 19. Int J Public Health. 2015. PMID: 25523137
-
Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant.Nicotine Tob Res. 2013 Mar;15(3):718-28. doi: 10.1093/ntr/nts186. Epub 2012 Sep 19. Nicotine Tob Res. 2013. PMID: 22992296 Free PMC article. Clinical Trial.
-
Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol.BMC Public Health. 2011 Sep 28;11:741. doi: 10.1186/1471-2458-11-741. BMC Public Health. 2011. PMID: 21955930 Free PMC article. Clinical Trial.
-
Awareness and use of tobacco quitlines: evidence from the Health Information National Trends Survey.J Health Commun. 2010;15 Suppl 3(0 3):264-78. doi: 10.1080/10810730.2010.526172. J Health Commun. 2010. PMID: 21154098 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
